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Relapse of the underlying disease is the commonest cause of treatment failure after allogeneic hemartopoietic stem cell transplantation (allorHSCT) 
and is related to a poorer outcome.1r3 Most relapses occur 
within the first two years of transplant.2 Chronic myeloid 
leukemia (CML) in first chronic phase is among those 
with the lowest rates (10%r30%) of relapse.4 On rare ocr
casions, an isolated extramedullary presentation is seen.2,3 
In a large retrospective multicenter survey by Békassy et 
al, extramedullary relapse was reported in only 6 of 2753 
(0.22%) grafted patients among the CML/myelodysplasr
tic subgroup.3 In this report, we describe a rare presenting 
feature of postrtransplant relapse of CML and discuss the 
main therapeutic alternatives in this setting.
CASE
An 18ryearrold male underwent an allorHSCT for CML 
in first late chronic phase in December 2006. He had 
been diagnosed with Philadelphia chromosomerposir
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an 18-year-old male underwent an allogeneic hematopoietic stem cell transplantation (allo-hsct) for 
chronic myeloid leukemia (cml) in the first late chronic phase. on day 132, he was readmitted to the 
hospital with nausea, vomiting and nodular lesions on endoscopy. a diagnosis of granulocytic sarcoma of 
the stomach was made. bone marrow cytogenetic analysis for the philadelphia chromosome and nested 
polymerase chain reaction for bcr-abl1 were both negative. immunosuppression was abruptly discon-
tinued, and by day 180, all gastric lesions had completely disappeared. however, there were histologi-
cal signs of graft-versus-host disease. the patient developed progressive anorexia and elevated hepatic 
enzymes, which prompted the reintroduction of cyclosporine. considering the risk of another relapse, 
imatinib mesylate (im) 600 mg/day was started. the patient´s condition improved, and there was no evi-
dence of disease recurrence at 36 months after relapse. relapse of cml is the commonest cause of treat-
ment failure after allo-hsct. on rare occasions, a localized extramedullary presentation is seen. unless 
properly treated, other extramedullary relapse sites and/or marrow infiltration usually occur. Withdrawal 
of immunosuppression, along with im therapy seems to be an acceptable approach in this setting.
tive (Ph+) CML in December 2003 and, since imatinib 
mesylate (IM) was not available as firstrline treatment, 
interferon alpha (IFNra) was used. Only a minor cytor
genetic response was observed after more than two years 
of treatment. As an HLArmatched unrelated male donor 
was available, an HSCT was performed. The conditionr
ing regimen consisted of busulfan, cyclophosphamide and 
antirthymocyte globulin. Cyclosporine and methotrexate 
were used for graftrversusrhost disease (GVHD) pror
phylaxis. Engraftment occurred at day 30. On day 63, 
he presented with a grade I GVHD of the skin, which 
was treated with oral steroids. After two weeks, ster
roids were progressively tapered off. Three months after 
transplant, cytogenetic analysis for the Ph chromosome 
and nested polymerase chain reaction (PCR) for BCRr
ABL1 were both negative. On day 132, he was readmitr
ted to hospital due to a threerday history of vomiting 
and nausea. The physical examination was unremarkr
able. The complete blood count and chemistry profile 
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were normal. Presuming occurrence of gastric GVHD, 
upper gastrointestinal endoscopy was performed. The 
exam revealed four erythematous round nodules on 
the gastric mucosa, with elevated borders and diamr
eters varying between 10 mm and 35 mm (Figure 1). 
Biopsies were performed and a histopathological/imr
munohistochemical examination showed a diffuse infilr
trate of immature myeloid cells in the mucosa (Figure 
2). Fluorescent in situ hybridization (FISH) analysis 
was positive for BCRrABL1, consistent with a diagnor
sis of granulocytic sarcoma (Figure 3). Bone marrow 
aspirate and biopsy showed no evidence of leukemia. 
Cytogenetic analysis and nested PCR remained negar
tive. There was no sign of active GVHD at that point, 
so immunosuppression was immediately stopped. After 
two weeks of drug discontinuation, a second endoscopy 
was performed. A significant regression of the two larger 
lesions and disappearance of the two smaller ones were 
observed . Given the response achieved, it was decided 
not to perform a donor lymphocyte infusion (DLI), and 
instead follow the remaining lesions with serial endosr
copies. On day 180, complete disappearance of the nodr
ules was observed. There were no signs of CML infilr
tration on histological evaluation, but signs of GVHD 
were present. The patient evolved with progressive 
anorexia and a significant increase in hepatic enzymes. 
Cyclosporine was reintroduced and, because of the risk 
of relapse, we decided to start with IM 600 mg/day. The 
patient´s condition improved, and subsequent endosr
copies showed no evidence of disease recurrence at 36 
months after relapse. No major drug toxicity was notr
ed. He developed chronic limited GVHD of the skin, 
and cyclosporine was being tapered, but otherwise the 
patient was well. The patient was in ongoing complete 
molecular remission (as evidenced by realrtime quantir
tative PCR negativity for BCRrABL1 transcripts) at a 
followrup of 36 months after relapse. 
DISCUSSION
Granulocytic sarcoma, also known as myeloid sarcoma 
or chloroma, is a localized extramedullary tumor mass 
consisting of immature cells of granulocytic lineage in 
different maturation steps.5 When presenting as postr
transplant relapse, it most often occurs before or conr
currently with the onset of marrow infiltration.2 In the 
first case, a misdiagnosis of lymphoma is frequently 
made.5,6 In our patient, FISH analysis of the gastric 
mucosa lesions confirmed the CML origin of the infilr
trating cells.
Figure 1. Upper gastrointestinal endoscopy showing 
erythematous round nodules with central ulceration and 
elevated borders, extending from the gastric fundus to the 
antrum-corpus transition zone (lesser curvature).
Figure 2. granulocytic sarcoma in gastric mucosa. a) low power field showing decreased glandular population and increased 
cellularity in the lamina propria on the right-hand side of the photograph; on the left-hand side, normal gastric mucosa (hematoxylin 
and eosin stain 50×). B ) Higher magnification showing neoplastic infiltration of the lamina propria by immature cells of myeloid 
lineage, red arrows (hematoxylin and eosin stain 400×).
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Detection of BCRrABL1 transcripts by PCR has a 
prominent role in the early prediction of fullrblown rer
lapse of CML.7 In our case, PCR for BCRrABL1 was 
negative at day 90 and was not capable of predicting 
overt disease, which was noticed less than two months 
later. This suggests a greater likelihood of isolated exr
tramedullary relapse. We cannot rule out whether the 
patient had a gastric lesion prior to transplantation. 
The underlying disease may have remained subclinical 
until the postrtransplant period, wherein an unfavorr
able immunological background may have contributed 
to the occurrence of overt disease.
Granulocytic sarcomas can involve virtually any 
organ.2,3 CML seems to have a tendency to relapse in 
bone, which in turn is associated with subsequent marr
row relapse and short survival.2 Other organs, particur
larly the gastrointestinal tract, are much less frequently 
affected.2,3,8,9 A recent case series by Cunningham anar
lyzed 35 first clinical extramedullary CML relapses afr
ter HSCT.2 In 24 of these cases, extramedullary sites 
were the first signs of relapse, at a median of 13 months 
postrHSCT, with or without simultaneous marrow rer
lapse. There were only two reported patients with gasr
trointestinal relapse, both of whom died.8,9 Most cases 
were treated with radiotherapy, and only half received 
chemotherapy. None of the cases studied reported use 
of IM. Thirty of the 35 patients died within 12 months 
of relapse.
Treatment of extramedullary relapse in CML has 
generally not resulted in long survival.4 A single rer
lapse site is usually followed, within months, by other 
extramedullary relapses and/or overt leukemia, unless 
prompt and aggressive treatment is undertaken.2,10 
Postrtransplant reports have varied in description of 
therapy details, and there does not seem to be a conr
sensus as to the best therapeutic approach in this setr
ting.2,3 
Surgery or radiotherapy alone may be effective 
in local disease control, but do not affect survival.10 
Encouraging remission rates are seen with DLI.11 At 
present, this is the standard frontrline approach for 
CML relapse after allografting, since it is capable of 
inducing longrterm molecular remissions and restorr
ing full donor chimerism.11 However, there is some 
evidence that granulocytic sarcomas exhibit a poorer 
response to chemotherapy and to the graftrversusrleur
kemia (GVL) effect, probably due to specific biologic 
properties of the leukemic cells at extramedullary sites, 
including increased tissue invasion and adhesion abilir
ties.12 Cells exhibiting tumor growth may, therefore, rer
quire longer exposure to treatment for complete eradir
cation. There are some reports of postrDLI extramedr
ullary relapse in the presence of continuous marrow 
remission, which suggests an uneven medullary and 
extramedullary GVL effect.13 In a study by Chong et 
al, patients with extramedullary relapse of a variety of 
hematological malignancies appeared to respond to cyr
totoxic therapy but not to DLI.14 While patients with 
chronic GVHD have a lower overall relapse risk, they 
may be more prone to delayed relapse at extramedulr
lary sites.14 Moreover, a study by Raiola et al showed 
a probability of DLIrrelated mortality of 44% for unr
related donor transplants as compared to a 9% rate for 
fullyrmatched siblings, mainly attributable to postr
DLI GVHD.15 Relapse type was the major predictor 
of response: patients with accelerated phase or blast 
crisis exhibited a response rate of only 36% to DLI, as 
opposed to 100% in those in molecular relapse alone.
A simple strategy for treating postrtransplant rer
lapse of CML is discontinuing immunosuppressive 
GVHD prophylaxis so as to restore the GVL effect, 
but successes have been anecdotal in the literature.16 
As mentioned in our report, considering the favorable 
response attained by the patient while withdrawing 
immunosuppression, as well as the side effects of DLI 
reported in the literature, particularly in the unrelated 
donor transplant setting, we decided to withhold this 
procedure.
The advent of IM, a tyrosine kinase inhibitor of 
BCRrABL fusionrgenerpositive cells, has revolutionr
ized the treatment of CML, and has had some promr
ising results in the postrtransplant relapse scenario.17 
However, the finding of granulocytic sarcoma lesions, 
as in the patient reported here, implies occurrence of 
relapse in blast crisis, wherein responses to IM tend to 
be of short duration. In a series of 128 patients with 
CML relapse after allografting, only 22% of those in 
Figure 3. Fluorescent in situ hybridization analysis of gastric 
mucosa lesion showing positivity for BCr-aBl1 , consistent with 
chronic myeloid leukemia origin (Vysis lS BCr/aBl dual Color, 
Single Fusion Translocation probe).
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blast crisis achieved a complete cytogenetic response 
with IM, and there were no complete molecular rer
sponses in this group.17
In a recent retrospective study of 16 cases of postr
transplant relapse of CML, the response rate to IM 
as frontrline therapy at relapse, or as secondr or thirdr
line therapy after failure of DLI and/or IFNrarwas 
as expected from treatment with DLI alone.18 Fifteen 
patients achieved cytogenetic and molecular responses 
(75% obtained RTrPCR negativity), and the patient 
who had relapsed in blast crisis achieved ongoing 
complete molecular remission, after a followrup of 45 
months, with combined therapy of IM and DLI. In all 
of these cases, IM showed an acceptable sidereffect pror
file, and no GVHD reaction was seen, nor did cases of 
prior GVHD worsen during treatment. Therefore, IM 
could be considered for firstrline therapy when DLI is 
not available or if the worrisome side effects of this pror
cedure are expected. In our case, the patient responded 
well to withdrawal of immunosuppression, as evidenced 
by serial endoscopies, and it seemed reasonable to keep 
him on maintenance therapy with IM (at a dose of 600 
mg daily), since the risk of overt relapse was high.
In conclusion, a greater awareness of the possibility 
of postrHSCT extramedullary relapse of CML once 
suspicious symptoms or lesions are encountered, such 
as in our case, may allow early treatment of a potentialr
ly curable disease. Doseradjustment or discontinuation 
of immunosuppression, along with IM therapy, seems 
to be an acceptable approach in this setting. A better 
understanding of the nature, prognosis, and treatment 
options of this rare condition may help patients achieve 
longrlasting remissions.
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